Improved Virus-Like Particle for Vaccine Development with Reduced Anti-Carrier Antibody Response


Executive Summary


Nanoparticles, such as virus-like particles (VLPs), have gained a lot of traction within the field of immunotherapy, largely inspired by the successful development of vaccines against hepatitis B and HPV-induced cervical cancer. Research to improve the immunogenic response against other types of antigens has led to testing various types of VLP coat proteins. Despite inducing a strong immune response in many trials, nanoparticle platforms in other trials exhibited low titer numbers, which were attributed to a strong anti-carrier immune response. MSU researchers have addressed this issue with an improved VLP by reducing anti-carrier immune response as well as increasing the stability of the carrier protein.


Description of Technology


This MSU technology is an enhanced VLP created to be a more powerful platform for vaccine development. When tested with an otherwise low immunogenic antigen, the modified VLP carrier induced a strong immune response while also significantly reducing anti-carrier antibodies. This technology is completely free of live virus and can be carried out by recombinant protein expression in E. coli, yeast, and cell-free protein synthesis, which provide flexibility in research and capacity in large-scale production.


Key Benefits

  • VLP capsid engineered to be more stable over current wild type platform.
  • Altered to reduce anti-carrier immune response.
  • Modified VLP platform is customizable for differing types of antigens for vaccine constructs



  • Vaccine for cancer immunotherapy
  • Modified VLP is highly adaptable for use in many diseases/disorders (e.g. HIV, H1N1, allergic asthma, etc.)


Patent Status:


Under Review


Licensing Rights Available:


Full licensing rights available


Inventors: Xuefei Huang, Suttipun Sungsuwan


Tech ID: TEC2017-0099


Patent Information:


For Information, Contact:

Su-Jun Lim
Technology Manager
Michigan State University